Previous Close | 8.63 |
Open | 7.89 |
Bid | 7.74 x 1200 |
Ask | 7.83 x 1100 |
Day's Range | 6.65 - 7.94 |
52 Week Range | 2.33 - 9.01 |
Volume | |
Avg. Volume | 350,570 |
Market Cap | 185.402M |
Beta (5Y Monthly) | 1.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.53 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for ABEO
Completion of FDA Inspections Marks Progress Towards PDUFA Date
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administration (FDA) has completed a Pre-License
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...